

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/160286 A1

(51) International Patent Classification:

A61P 25/04 (2006.01) C07D 471/04 (2006.01)
A61P 29/00 (2006.01) C07D 498/02 (2006.01)
C07D 213/80 (2006.01)

(21) International Application Number:

PCT/US2025/012773

(22) International Filing Date:

23 January 2025 (23.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/624,672 24 January 2024 (24.01.2024) US
63/712,366 25 October 2024 (25.10.2024) US

(71) Applicant: SITEONE THERAPEUTICS, INC.

[US/US]; 951-3 Gateway Boulevard, South, San Francisco,
CA 94080 (US).

(72) Inventors: ZHU, Jie; C/o Siteone Therapeutics, Inc., 951-3

Gateway Blvd., South San Francisco, CA 94080 (US).

DUNLAP, Lee; c/o Siteone Therapeutics, Inc., 951-3 Gate-

way Boulevard, South, San Francisco, CA 94080 (US).

ZHANG, Guoliang; c/o Siteone Therapeutics, Inc., 951-3

Gateway Boulevard, South, San Francisco, CA 94080 (US).

LE, Ryan; c/o Siteone Therapeutics, Inc., 951-3 Gate-

way Boulevard, South, San Francisco, CA 94080 (US).

BEAR, Brian; c/o Siteone Therapeutics, Inc., 951-3 Gate-

way Boulevard, South, San Francisco, CA 94080 (US).

MULCAHY, John; C/o Siteone Therapeutics, Inc., 951-3

Gateway Blvd., South San Francisco, CA 94080 (US).

(74) Agent: STRONG, Katie et al.; 30256 - Squire PB (Pal Of-

fice), 555 California Street, Suite 550, San Francisco, CA

94104 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,

WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

WO 2025/160286 A1

(54) Title: 2-ARYL CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAV1.8 FOR THE TREATMENT OF PAIN

(57) Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 1-723.